Also turning heads: Nico Collins entering the next tier of top wideouts, Jim Harbaugh’s Chargers and the Commanders turning the tempo up with a rookie QB.
Netherlands-based managing general agent specialises in financial lines Related Stories KCC pegs insured loss from Helene at $6.4bn Daily Digest: Aviation insurance mega-trial starts, New Lloyd’s fee structure welcomed, Swiss Re on outdated models Daily Digest: Aviation insurance mega-trial starts, Lloyd’s new fee structure welcomed, Swiss Re on outdated models
New estimate in line with the $5bn to $10bn insured loss range issued over the past week by various analysts Related Stories Daily Digest: Aviation insurance mega-trial starts, New Lloyd’s fee structure welcomed, Swiss Re on outdated models Daily Digest: Aviation insurance mega-trial starts, Lloyd’s new fee structure welcomed, Swiss Re on outdated models…
Catch up on the essential news and analysis from the Insurance Day experts Related Stories Ryan Specialty acquires Ardonagh’s Geo Europe KCC pegs insured loss from Helene at $6.4bn Daily Digest: Aviation insurance mega-trial starts, Lloyd’s new fee structure welcomed, Swiss Re on outdated models
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
SCAN Health Plan and Astrana Health recently launched SCAN Allied, a Medicare Advantage plan designed for the Asian older adult population. It includes access to a network of culturally competent providers, specialists and pharmacies from Astrana Health. The post SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults appeared first on MedCity News.
Lilly Medicine Foundry will research new ways to manufacture medicines. Eli Lilly says in addition to supporting the manufacturing of drugs for clinical trials, manufacturing innovations from the site will be transferred to the company’s other facilities for use in full-scale drug production. The post Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in…
The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
